You might also like
Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that encompass instruments, software, services, and consumables for the entire laboratory workflow . The company operates through three main business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab . Agilent's offerings are designed to enhance laboratory efficiency and effectiveness, catering to a wide range of scientific and industrial applications .
- Agilent CrossLab - Focuses on services, software, informatics, and consumables, designed to improve customer outcomes and is vendor neutral, serving customers regardless of their instrument choices .
- Diagnostics and Genomics - Includes cell analysis, nucleic acid solutions, and pathology solutions, with growth in nucleic acid solutions and reagent partnership businesses .
- Life Sciences and Applied Markets - Provides solutions such as liquid chromatography, mass spectrometry, gas chromatography, and spectroscopy .
| Revenue by Segment - in Millions of USD | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences and Applied Markets | 928 | 3,856 | 846 | 754 | 782 | 833 | 3,215 | 647 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostics and Genomics | 356 | 1,409 | 407 | 417 | 385 | 442 | 1,651 | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Agilent CrossLab | 404 | 1,568 | 405 | 402 | 411 | 426 | 1,644 | 696 | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Products | 1,232 | 5,051 | 1,209 | 1,125 | 1,121 | 1,217 | 4,672 | 1,200 | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Services and Other | 456 | 1,782 | 449 | 448 | 457 | 484 | 1,838 | 481 | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Analytical Lab Consumables | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Diagnostics and Genomics Solutions | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Informatics and Other | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total Revenue | 1,688 | 6,833 | 1,658 | 1,573 | 1,578 | 1,701 | 6,510 | 1,681 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue by Geography - in Millions of USD | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Americas | 702 | 2,732 | 630 | 637 | 626 | 68 | 2,573 | 669 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Europe | 433 | 1,754 | 458 | 426 | 432 | 454 | 1,770 | 463 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Asia Pacific | 553 | 2,347 | 570 | 510 | 520 | 567 | 2,167 | 549 | ||||||||||||||||||||||||||||||||||||||||||||||||
| - United States | - | 2,410 | - | - | - | - | 2,246 | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| - China including Hong Kong | - | 1,383 | - | - | - | - | 1,217 | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| - Rest of the World | - | 3,040 | - | - | - | - | 3,047 | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total Revenue | 1,688 | 6,833 | 1,658 | 1,573 | 1,578 | 1,701 | 6,510 | 1,681 | ||||||||||||||||||||||||||||||||||||||||||||||||
| KPIs - Metric (Unit, Scale) | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Days sales outstanding (days) | - | 69 | - | - | - | - | 70 | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory days on-hand (days) | - | 120 | - | - | - | - | 111 | - |
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Angelica A. Reimann Executive | Senior Vice President and President, ACG | None | Angelica Reimann has been with Agilent for over 25 years and became President of the Agilent CrossLab Group in February 2024. | |
Mike Zhang Executive | Senior Vice President and President, AMG | None | Mike Zhang joined Agilent in 2002 and became President of the Applied Markets Group in August 2024. He has extensive experience in gas chromatography and mass spectrometry. | |
Padraig McDonnell Executive | President and CEO | None | Padraig McDonnell became CEO in May 2024 after serving as COO and CEO-elect. He has over 26 years of experience at Agilent and its predecessor, Hewlett-Packard Co.. | View Report → |
Robert W. McMahon Executive | Senior Vice President and CFO | Board Member at Orasure Technologies, Inc. | Robert McMahon has been CFO since September 2018. He previously held CFO roles at Hologic, Inc., and senior finance roles at Johnson & Johnson. | |
Dow R. Wilson Board | Director | Board Member at Siemens Healthineers AG | Dow Wilson has been a director since 2018. He is the former CEO of Varian Medical Systems and has extensive experience in the healthcare industry. | |
Heidi K. Kunz Board | Director | Board Member at Phathom Pharmaceuticals, Inc. | Heidi Kunz has been a director since 2000. She has extensive financial expertise and previously served as CFO for several companies. | |
Koh Boon Hwee Board | Non-Executive Chairperson of the Board | Non-Executive Chairman of Singapore Exchange Ltd.; Managing Partner at Altara Ventures Pte. Ltd.; Non-Executive Chairperson of Sunningdale Tech Ltd. | Koh Boon Hwee has been a director since 2003 and Chairperson since 2017. He brings extensive leadership and governance experience. | |
Mala Anand Board | Director | Corporate Vice President, Customer Experience at Microsoft | Mala Anand has been a director since 2019 and is also a Corporate VP at Microsoft, focusing on customer experience. | |
Otis W. Brawley Board | Director | Board Member at Incyte Corporation, Lyell Immunopharma, Inc., and PDS Biotechnology Corp | Otis Brawley has been a director since 2021. He is a Bloomberg Distinguished Professor at Johns Hopkins University and serves on multiple biotech boards. | |
Sue H. Rataj Board | Director | None | Sue Rataj has been a director since 2015. She previously served as non-Executive Chair of Cabot Corporation and held senior roles at BP. |
-
Given that the Applied Markets Group (AMG) represents $1.3 billion in annual revenue compared to the Agilent CrossLab Group (ACG) at $2.7 billion and Life Sciences and Diagnostics Group (LDG) at $2.5 billion, what are your plans to accelerate growth in AMG, and how do you plan to address potential market saturation in these applied markets?
-
You mentioned that your pathology business grew high single digits in Q4 and that genomics posted low single-digit growth after a period of declines. Given the challenging genomics market and your recent strategy pivot, how sustainable is this growth, and what are the key risks that could impact your performance in genomics moving forward?
-
With the launch of the Infinity III LC series and your expectations for increased demand starting in Q1, how confident are you in capturing market share given that competitors may have already benefited from a refresh of their installed base? What strategies do you have in place to differentiate Agilent's offerings in a potentially saturated market?
-
Regarding your guidance for fiscal year 2025, you mentioned that the "error bars" around your assumptions are wider than normal due to uncertainties such as the LC replacement cycle recovery, China stimulus, and U.S. market sentiment. Could you elaborate on the specific scenarios that could impact your guidance, and how you are preparing to mitigate potential downside risks?
-
With the acquisition of BIOVECTRA to expand your CDMO services, how do you plan to integrate this new business to drive growth, and what challenges do you anticipate in scaling up capabilities in rapidly growing therapeutic modalities like peptide synthesis and gene editing therapies? Additionally, how significant is the competitive landscape in these areas, and how will you differentiate your services?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
PerkinElmer Inc. | Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. |
Shimadzu Corporation | Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. |
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Affymetrix, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Avecia | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Leica Biosystems, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Roche Ventana Medical Systems, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Sartorius | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
BIOVECTRA | 2024 | Agilent Technologies acquired 100% of BIOVECTRA’s stock for $915 million in cash, including the assumption of $24 million in interest‑free loans with repayment through 2040, to expand its CDMO capabilities and enhance expertise in high-growth areas like GLP‑1 and gene editing, adding significant customer relationships and projected FY2024 revenue of $140–150 million. |
Polymer Standards Service GmbH (PSS) | 2022 | Agilent acquired PSS for $41 million, contributing $19 million of goodwill and $35 million in other intangible assets, which strengthens its advanced materials and biopharma portfolio through enhanced polymer characterization expertise and support via Agilent’s instrumentation. |
Advanced Artificial Intelligence Technology | 2022 | This acquisition involved contingent consideration based on milestone payments estimated using a Monte Carlo simulation; it resulted in $21 million of recorded other intangible assets and $18 million of cash used, with an associated $150 million in amortization expense but no addition to goodwill, reflecting its strategic and financial impact. |
Recent developments and announcements about A.
Earnings
New Earnings (Q1 2025)
·Feb 27, 2025, 12:10 AMView full earnings summary →Agilent's Q1 PFAS solutions soared 70% (+75bps), while Infinity III replacements fueled orders outpacing revenue. Book-to-bill >1 signals strong demand, though margins slipped to 54.7% from FX and mix. Growth outlook remains upbeat, driven by continued PFAS gains.
8-K Filings
8-K Filing
·Mar 3, 2025, 10:51 PMFinancial ExhibitsOther EventsView full 8-K filing →Agilent Technologies filed an 8-K detailing a reorganization into three segments—Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The filing includes recast historical financials and a goodwill reallocation of $1.27B.